Physician profile
Arnaldo Isa
NPI 1952390452
$104,862.37
in general payments reported to CMS, 2019-2025
84 companies · $4,993 in 2025
The $4,993 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $26K · 2021: $24K · 2022: $6,194 · 2023: $3,559 · 2024: $5,919 · 2025: $4,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,226 · Education: $43.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,202.10 |
| Consulting Fee | $1,226.25 |
| Education | $43.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $52,365.80 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genzyme Corporation | $18,492.59 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $11,219.06 | 2020-2021 | |
| Abbvie INC. | $2,186.73 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $1,639.20 | 2019-2025 | Ingrezza |
| Biogen, INC. | $1,396.85 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Janssen Scientific Affairs, LLC | $1,302.15 | 2024-2025 | |
| Ucb, INC. | $1,205.90 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $910.09 | 2019-2025 | |
| Emd Serono, INC. | $876.66 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $816.52 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Allergan, INC. | $806.01 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $785.85 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $767.29 | 2023-2025 | |
| Lundbeck LLC | $640.98 | 2019-2025 | Rexulti, Vyepti |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $539.71 | 2019-2025 | |
| Argenx US, INC. | $459.50 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $445.87 | 2019-2025 | Qelbree |
| Amgen INC. | $411.54 | 2019-2025 | Uplizna |
| Mdd US Operations, LLC | $405.99 | 2019-2025 | Gocovri, Gocovri |
| Amneal Pharmaceuticals LLC | $401.79 | 2019-2025 | Crexont, Rytary |
| Genentech USA, INC. | $375.65 | 2021-2025 | Ocrevus Zunovo, Ocrevus, Evrysdi |
| Jazz Pharmaceuticals INC. | $352.04 | 2020-2025 | Xywav, Epidiolex |
| Sk Life Science, INC. | $351.30 | 2020-2025 | |
| Acorda Therapeutics, INC | $331.43 | 2019-2023 | Inbrija, Ampyra |
| Celgene Corporation | $297.76 | 2021-2025 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $251.30 | 2023-2025 | Hyqvia, Gammagard |
| Tanabe Pharma America, INC. | $247.50 | 2020-2025 | Radicava |
| Neurelis, INC. | $226.55 | 2020-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $207.41 | 2021-2025 | Firdapse |
| Grifols USA, LLC | $204.36 | 2019-2025 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $186.06 | 2021-2024 | Ztlido |
| Janssen Pharmaceuticals, INC | $184.45 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $182.50 | 2023-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $177.03 | 2019-2023 | Nuplazid |
| Ge Healthcare | $159.05 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $156.48 | 2024-2025 | Ponvory |
| Tg Therapeutics, INC. | $152.98 | 2023-2025 | |
| Livanova USA, INC. | $152.33 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Harmony Biosciences LLC | $149.66 | 2020-2021 | |
| Biotronik INC. | $140.39 | 2025 | Biomonitor |
| Mallinckrodt Hospital Products INC. | $138.98 | 2020-2025 | Acthar |
| Upsher-Smith Laboratories LLC | $134.80 | 2020-2023 | |
| Horizon Therapeutics Plc | $132.57 | 2021-2023 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $125.83 | 2022 | |
| Mallinckrodt Enterprises LLC | $116.22 | 2019 | |
| Alnylam Pharmaceuticals INC. | $110.65 | 2020-2023 | Onpattro |
| Merz Pharmaceuticals, LLC | $105.35 | 2024-2025 | Xeomin |
| Banner Life Sciences, LLC | $98.03 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $96.86 | 2023-2024 | Aptiom |
| Avanir Pharmaceuticals, INC. | $95.54 | 2019-2021 | |
| Bausch Health US, LLC | $91.97 | 2019 | |
| Kyowa Kirin, INC. | $90.36 | 2020-2024 | Nourianz |
| Averitas Pharma INC. | $78.87 | 2023-2024 | Qutenza |
| Avadel Cns Pharmaceuticals, LLC | $77.33 | 2023-2024 | Lumryz |
| Xeris Pharmaceuticals, INC. | $65.21 | 2022-2025 | Keveyis |
| Axsome Therapeutics, INC. | $63.43 | 2024-2025 | Sunosi |
| Csl Behring | $61.74 | 2024 | Hizentra |
| Zyla Life Sciences, INC. | $60.42 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $48.64 | 2019-2022 | |
| Strongbridge US INC. | $40.81 | 2020 | |
| Janssen Biotech, INC. | $40.54 | 2025 | |
| Assertio Therapeutics, INC. | $33.54 | 2020 | |
| Sandoz INC. | $31.03 | 2023 | |
| Globus Medical, INC. | $29.96 | 2025 | Senza |
| Adamas Pharmaceuticals, INC. | $29.83 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $26.22 | 2020-2021 | |
| Impel Pharmaceuticals INC. | $22.89 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $22.56 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $21.01 | 2020 | |
| Cala Health, INC. | $20.91 | 2022 | |
| Merz North America, INC. | $20.36 | 2020 | |
| Avion Pharmaceuticals | $20.17 | 2022 | |
| Abbott Laboratories | $19.37 | 2023 | Proclaim |
| Revance Therapeutics, INC. | $18.11 | 2025 | Daxxify |
| Medtronic, INC. | $17.81 | 2021 | |
| Corium, LLC | $17.10 | 2022 | |
| Akcea Therapeutics, INC. | $15.90 | 2019 | |
| Impel Pharmaceuticals LLC | $15.31 | 2025 | Trudhesa |
| Inspire Medical Systems, INC. | $15.20 | 2025 | Inspire |
| C2n Diagnostics, LLC | $14.98 | 2025 | Precivityad2 |
| Boston Scientific Corporation | $13.65 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnaldo Isa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.